Marina Biotech

About:

Patient Centric Care for Hypertension and Pain

Top Investors: Crede CapitalGroup, Thynk Capital, Steven T. Newby

Description:

Our mission is to provide effective and patient centric treatment for hypertension- including resistant hypertension. In doing so creating a universal platform for the effective treatment of hypertension as well as for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in our pipeline. The company commercial product Prestalia® is approved by US FDA for the treatment of hypertension and being commercialized through the DyrctAxess platform. The company is also developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic.

Total Funding Amount:

$24.9M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

City Of Industry, California, United States

Founded Date:

1983-01-01

Contact Email:

admin(AT)marinabio.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2018-07-25

IPO Status:

Public

Industries: